加载中
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$7.06
+US$0.25 · +3.67%
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
前收盘价
US$7.06
+US$0.25 · +3.67%
盘中时间采用ET。市场数据可能有所延迟。
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
日内区间
当前US$7.06
52周区间
当前US$7.06
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
54
合理估值
情绪
51
多空交织
风险
76
高风险
动量
31
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
日内区间
当前US$7.06
52周区间
当前US$7.06
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7.43亿 USD | 10.44亿 USD | 10.49亿 USD | 11.18亿 USD | 17.74亿 USD |
| 销货成本 | 3.92亿 USD | 6.68亿 USD | 6.89亿 USD | 6.45亿 USD | 9.8亿 USD |
| 毛利 | 3.51亿 USD | 3.75亿 USD | 3.6亿 USD | 4.73亿 USD | 7.93亿 USD |
| 研究与开发 | 5380万 USD | 7070万 USD | 1.11亿 USD | 1.88亿 USD | 2.35亿 USD |
| 销售、一般及管理费用 | 1.87亿 USD | 2.99亿 USD | 3.57亿 USD | 3.4亿 USD | 3.49亿 USD |
| 营业费用 | 2.4亿 USD | 4.84亿 USD | 10.86亿 USD | 6.43亿 USD | 4.52亿 USD |
| 利息支出 | 5930万 USD | 7100万 USD | 8790万 USD | 3730万 USD | 3450万 USD |
| 折旧和摊销 | 9580万 USD | 1.09亿 USD | 1.25亿 USD | 1.43亿 USD | 1.24亿 USD |
| 营业利润 | 1.1亿 USD | −1.09亿 USD | −7.26亿 USD | −1.7亿 USD | 3.41亿 USD |
| 净利润 | 5260万 USD | −1.91亿 USD | −7.61亿 USD | −2.12亿 USD | 2.2亿 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Schwab International Equity ETFSCHF8033.88万0.12%674.08亿 USD0.03%US$27.27+0.66%
State Street SPDR Portfolio Developed World ex-US ETFSPDW5230.83万0.13%404.62亿 USD0.03%US$49.98+0.64%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ4214.96万3.18%13亿 USD0.48%US$35.59+0.57%
Schwab Fundamental International Large Company Index ETFFNDF2492.04万0.10%253.2亿 USD0.25%US$53.61+0.46%
Avantis U.S. Small Cap Value ETFAVUV2010.6万0.06%308.51亿 USD0.25%US$119.64-0.41%
State Street SPDR S&P Biotech ETFXBI1115.11万0.11%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM962.14万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI948.01万0.00%2.3万亿 USD0.03%US$381.94+0.63%Schwab International Equity ETFSCHFState Street SPDR Portfolio Developed World ex-US ETFSPDWPrincipal Exchange-Traded Funds - Principal International Equity ETFPIEQSchwab Fundamental International Large Company Index ETFFNDFAvantis U.S. Small Cap Value ETFAVUVState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
